Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
LNQ (LinqAI) fluctuates 43.0% in 24 hours: X Platform Cashtags feature restored and Horizon listing vote drive exposure

LNQ (LinqAI) fluctuates 43.0% in 24 hours: X Platform Cashtags feature restored and Horizon listing vote drive exposure

Bitget PulseBitget Pulse2026/04/16 17:58
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, the price of LNQ rose from a low of $0.00214 to a high of $0.00306 and is currently quoted at $0.00218, with a price fluctuation range of 43.0%. The 24-hour trading volume is approximately $250,000-$300,000 (CoinGecko data: $294,759; CMC data: $159.35K), with a market capitalization around $900,000 and a volume/market cap ratio of roughly 27%-30%, indicating increased trading activity.

Brief Analysis of the Unusual Move

- The Cashtags feature was launched on Platform X on April 15 (US/Canada iPhone), allowing for real-time financial data display. Previously, tags like $LNQ were restricted; the LinqAI team and COO responded immediately, stating that “cashtags will no longer be penalized, as this is the sprint period,” enhancing token exposure.

- On April 15, the MESSIER project announced a Horizon listing vote driven by $LNQ and other tokens: “Momentum is strong, each vote unlocks compliant private trading,” increasing community interaction.

- LinqAI ecosystem points multiplier snapshot (3x loyalty) was targeted at users from the 3/25 snapshot, further incentivizing community participation.

There was a minor net outflow on-chain (-$115 overall), with no significant whale activity observed.

Market Opinion and Outlook

The mainstream community sentiment is positive, with discussions on Platform X focusing on Cashtags benefits and the Horizon vote "activating utility," viewed by the team as “the final sprint.” Analysts have not issued specific predictions, and short-term volatility may continue (high volatility), with risk stemming from the possibility of pullbacks in the small market cap. Keep an eye on listing developments and sustained platform exposure.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market